J
Joseph J. Drabick
Researcher at Penn State Cancer Institute
Publications - 173
Citations - 4495
Joseph J. Drabick is an academic researcher from Penn State Cancer Institute. The author has contributed to research in topics: Cancer & Pembrolizumab. The author has an hindex of 28, co-authored 165 publications receiving 3628 citations. Previous affiliations of Joseph J. Drabick include Uniformed Services University of the Health Sciences & Walter Reed Army Medical Center.
Papers
More filters
Journal ArticleDOI
Acoustic separation of circulating tumor cells
Peng Li,Zhangming Mao,Zhangli Peng,Lanlan Zhou,Yuchao Chen,Po-Hsun Huang,Cristina I. Truica,Joseph J. Drabick,Wafik S. El-Deiry,Ming Dao,Subra Suresh,Tony Jun Huang +11 more
TL;DR: The development of an acoustic-based microfluidic device that is capable of high-throughput separation of CTCs from peripheral blood samples obtained from cancer patients is demonstrated and offers the potential to serve as an invaluable supplemental tool in cancer research, diagnostics, drug efficacy assessment, and therapeutics.
Journal ArticleDOI
Theory and in vivo application of electroporative gene delivery.
Stella Somiari,Jill Glasspool-Malone,Joseph J. Drabick,Richard Gilbert,Richard Heller,Mark J. Jaroszeski,Robert W. Malone +6 more
TL;DR: An overview of the theory and practice of electroporative gene transfer is provided to aid researchers that wish to employ the method for preclinical and translational gene therapy, NAV, and functional genomic research.
Journal ArticleDOI
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
Ming Yin,Monika Joshi,Richard P. Meijer,Richard P. Meijer,Michael Glantz,Sheldon L. Holder,Harold A. Harvey,Matthew Kaag,Elisabeth E. Fransen van de Putte,Simon Horenblas,Joseph J. Drabick +10 more
TL;DR: The results support the use of cisplatin-based combination neoadjuvant chemotherapy in muscle-invasive bladder cancer patients and suggest that NCT should be standard care in MIBC, and MVAC might have superior overall survival compared with GC (with or without carboplatin data) in the neoadedjuvant setting.
Journal ArticleDOI
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Antoni Ribas,Theresa Medina,Shivaani Kummar,Asim Amin,Anusha Kalbasi,Joseph J. Drabick,Minal A. Barve,Gregory A. Daniels,Deborah J. Wong,Emmett V. Schmidt,Albert Candia,Robert L. Coffman,Abraham C.F. Leung,Robert Janssen +13 more
TL;DR: Early data demonstrate that the combination of pembrolizumab with intratumoral SD-101 is well tolerated and can induce immune activation at the tumor site, which can potentially increase clinical efficacy with minimal additional toxicity relative to PD-1 blockade alone.
Journal ArticleDOI
Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization.
TL;DR: It is demonstrated that in vivo skin EP may be used to increase transgene expression up to an average of 83-fold relative to naked DNA injection and applications for these findings include NAV-based modulation of immune responses to pathogens, allergens, and tumor-associated antigens and the modification of tolerance.